

File No. 161245

Committee Item No. 8

Board Item No. \_\_\_\_\_

**COMMITTEE/BOARD OF SUPERVISORS**

**AGENDA PACKET CONTENTS LIST**

Committee: Budget & Finance Committee

Date December 7, 2016

Board of Supervisors Meeting

Date \_\_\_\_\_

**Cmte Board**

- |                                     |                          |  |
|-------------------------------------|--------------------------|--|
| <input type="checkbox"/>            | <input type="checkbox"/> | Motion                                       |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Resolution                                   |
| <input type="checkbox"/>            | <input type="checkbox"/> | Ordinance                                    |
| <input type="checkbox"/>            | <input type="checkbox"/> | Legislative Digest                           |
| <input type="checkbox"/>            | <input type="checkbox"/> | Budget and Legislative Analyst Report        |
| <input type="checkbox"/>            | <input type="checkbox"/> | Youth Commission Report                      |
| <input type="checkbox"/>            | <input type="checkbox"/> | Introduction Form                            |
| <input type="checkbox"/>            | <input type="checkbox"/> | Department/Agency Cover Letter and/or Report |
| <input type="checkbox"/>            | <input type="checkbox"/> | MOU  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Grant Information Form                       |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Grant Budget                                 |
| <input type="checkbox"/>            | <input type="checkbox"/> | Subcontract Budget                           |
| <input type="checkbox"/>            | <input type="checkbox"/> | Contract/Agreement                           |
| <input type="checkbox"/>            | <input type="checkbox"/> | Form 126 – Ethics Commission                 |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Award Letter                                 |
| <input type="checkbox"/>            | <input type="checkbox"/> | Application                                  |
| <input type="checkbox"/>            | <input type="checkbox"/> | Public Correspondence                        |

**OTHER (Use back side if additional space is needed)**

<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____

Completed by: Linda Wong Date December 2, 2016

Completed by: Linda Wong Date \_\_\_\_\_

1 [Accept and Expend Grant - National Institutes of Health - Mid-Career Award in Patient-  
2 Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV - \$157,235]

3 **Resolution retroactively authorizing the Department of Public Health to accept and**  
4 **expend a grant in the amount of \$157,235 from National Institutes of Health to**  
5 **participate in a program entitled Mid-Career Award in Patient-Oriented Substance Use**  
6 **Research Addressing Opioids, Chronic Pain, and HIV for the period of September 1,**  
7 **2016, through August 31, 2017.**

8  
9 WHEREAS, National Institutes of Health has agreed to fund Department of Public  
10 Health (DPH) in the amount of \$157,235 for the period of September 1, 2016, through August  
11 31, 2017; and

12 WHEREAS, The full project period of the grant starts on September 1, 2016, and ends  
13 on August 31, 2021, with years two, three, four, and five subject to availability of funds and  
14 satisfactory progress of the project; and

15 WHEREAS, As a condition of receiving the grant funds, National Institutes of Health  
16 requires the City to enter into an agreement (Agreement), a copy of which is on file with the  
17 Clerk of the Board of Supervisors in File No. 161245; which is hereby declared to be a part of  
18 this Resolution as if set forth fully herein; and

19 WHEREAS, The purpose of this project will support the candidate's development as a  
20 mentor and substance use researcher, while completing a study of the impact of reduced or  
21 discontinued opioid therapy on patients infected with HIV; and

22 WHEREAS, An Annual Salary Ordinance amendment is not required as the grant  
23 partially reimburses DPH for one existing position, one Senior Physician Specialist (Job Class  
24 No. 2232) at .40 FTE for the period of September 1, 2016, through August 31, 2017; and  
25

1           WHEREAS, A request for retroactive approval is being sought because DPH did not  
2 receive the full award agreement until August 10, 2016, for a project start date of September  
3 1, 2016; and

4           WHEREAS, The budget includes a provision for indirect costs in the amount of \$9,819;  
5 now, therefore, be it

6           RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant  
7 in the amount of \$157,235 from National Institutes of Health; and, be it


8           FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and  
9 expend the grant funds pursuant to San Francisco Administrative Code, Section 10.170-1;  
10 and, be it

11           FURTHER RESOLVED, That the Director of Health is authorized to enter into the  
12 Agreement on behalf of the City.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

RECOMMENDED:




Barbara A. Garcia, MPA  
Director of Health

APPROVED:



for Office of the Mayor



for Office of the Controller

File Number: \_\_\_\_\_  
(Provided by Clerk of Board of Supervisors)

**Grant Resolution Information Form**  
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV**

2. Department: **Department of Public Health  
Center of Public Health Research**

3. Contact Person: **Phillip Coffin, MD** Telephone: **415-437-6282**

4. Grant Approval Status (check one):

Approved by funding agency

Not yet approved

5. Amount of Grant Funding Approved or Applied for: **\$764,671 in the 5-year project period**  
(Year 1 = \$157,235; Year 2 = \$153,479; Year 3 = \$151,319; Year 4 = \$151,319; Year 5 = \$151,319)

6a. Matching Funds Required: **\$0**

b. Source(s) of matching funds (if applicable):

7a. Grant Source Agency: **National Institutes of Health (NIH)**

b. Grant Pass-Through Agency (if applicable):

8. Proposed Grant Project Summary: **This K24 award will support the candidate's development as a mentor and substance use researcher, while completing a study the impact of reduced or discontinued opioid therapy on patients infected with HIV. The candidate will complete advanced training in mentoring and meet regularly with senior mentors to improve his mentoring, while increasing his mentoring load throughout the award period. He will also enhance his ability to excel as a substance use researcher addressing opioid use and chronic pain by completing American Board of Addiction Medicine board certification and the American Pain Society Fundamentals of Pain Medicine course, completing independent structured reading programs addressing pain research as well as biostatistics and research design, and gaining direct clinical experience in chronic pain management. In addition, the candidate will pursue new research to examine the impact of discontinuation of prescription opioid use among HIV-positive patients. The candidate will perform extensive chart extraction research on 600 patients prescribed opioids for chronic pain (300 HIV-positive, 300 frequency-matched HIV-negative) in years 1-2 and 3-4 of the award period in order to characterize the trajectory of opioid prescribing and rationale for continuation or changes in opioid therapy, compare opioid prescribing patterns and yellow flag behaviors among HIV-positive and HIV-negative patients, and prospectively assess the relationship between receipt of prescription opioids and clinic care of HIV-positive and HIV-negative patients. Analysis will involve pooled logistic regression modeling adjusted for frequency-matching strata, and generalized estimating equations, depending on the hypothesis being tested.**

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Approved Year one project: Start-Date: 09/01/2016 End-Date: 08/31/2017

Full project period: Start-Date: 09/01/2016 End-Date: 08/31/2021

10a. Amount budgeted for contractual services: **\$49,684 in Year 1**  
**\$234,916 in the 5-year project period**

b. Will contractual services be put out to bid? **No**

c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N/A**

d. Is this likely to be a one-time or ongoing request for contracting out? **N/A**

11a. Does the budget include indirect costs?  Yes  No

b1. If yes, how much? **\$9,819 in Year 1; \$41,095 in the 5-year project period**

b2. How was the amount calculated?

c1. If no, why are indirect costs not included?

Not allowed by granting agency

To maximize use of grant funds on direct services

Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs?

12. Any other significant grant requirements or comments:

**We respectfully request for approval to accept and expend these funds retroactive to September 01, 2016. The Department received the full award agreement on August 10, 2016.**

Grant Code: **HCIV08/1700**

**\*\*Disability Access Checklist\*\*\*(Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

Existing Site(s)

Existing Structure(s)

Existing Program(s) or Service(s)

Rehabilitated Site(s)

Rehabilitated Structure(s)

New Program(s) or Service(s)

New Site(s)

New Structure(s)

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:


*FW*  
Matthew Valdez

(Name)

EEO Programs Manager, Office of Equal Employment Opportunity and Cultural Competency

(Title)

Date Reviewed: 10-25-16


  
(Signature Required)

**Department Head or Designee Approval of Grant Information Form:**

Barbara A. Garcia, MPA  
(Name)

Director of Health  
(Title)

Date Reviewed: 10/28/16

  
(Signature Required)

Principal Investigator/Program Director (Last, first, middle):							
DETAILED BUDGET FOR INITIAL BUDGET PERIOD				DIRECT COSTS ONLY		FROM	THROUGH
						1-Sep-16	31-Aug-17
PERSONNEL (Applicant organization only)		TYPE APPT. (months)	% EFFORT ON PROJ.	INST. BASE SALARY	DOLLAR AMOUNT REQUESTED (omit cents)		
NAME	ROLE ON PROJECT				SALARY REQUESTED	FRINGE BENEFITS	TOTALS
Phillip Coffin, MD		12	0.40000	185,100	74,040	-	74,040
SUBTOTALS					74,040	-	74,040
CONSULTANT COSTS							
EQUIPMENT (Itemize)							
SUPPLIES (Itemize by category)							
TRAVEL							
							-
INPATIENT							-
OUTPATIENT							-
ALTERATIONS AND RENOVATIONS (Itemize by category)							
OTHER EXPENSES (Itemize by category)							
SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD							74,040
CONSORTIUM/CONTRACTUAL				TOTAL Subcontract		49,684	
				FACILITIES AND ADMINISTRATIVE COSTS		9,819	
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 9a, Face Page)							133,543
Page _____							Form Page 2



Principal Investigator/Program Director (Last, first, middle):					FROM	THROUGH	
DETAILED BUDGET FOR INITIAL BUDGET PERIOD			DIRECT COSTS ONLY		1-Sep-17	31-Aug-18	
PERSONNEL (Applicant organization only)				DOLLAR AMOUNT REQUESTED (omit cents)			
NAME	ROLE ON PROJECT	TYPE APPT. (months)	% EFFORT ON PROJ.	INST. BASE SALARY	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
Phillip Coffin, MD		12	0.40000	185,100	74,040	-	74,040
<b>SUBTOTALS</b>					<b>74,040</b>	<b>-</b>	<b>74,040</b>
<b>CONSULTANT COSTS</b>							
<b>EQUIPMENT (Itemize)</b>							
<b>SUPPLIES (Itemize by category)</b>							
<b>TRAVEL</b>							
							-
							-
							-
<b>ALTERATIONS AND RENOVATIONS (Itemize by category)</b>							
							-
<b>OTHER EXPENSES (Itemize by category)</b>							
							-
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>74,040</b>
<b>CONSORTIUM/CONTRACTUAL</b>				<b>TOTAL Subcontract</b>		<b>47,928</b>	
				<b>FACILITIES AND ADMINISTRATIVE COSTS</b>		<b>7,819</b>	
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 9a, Face Page)</b>							<b>129,787</b>

Principal Investigator/Program Director (Last, first, middle):							
DETAILED BUDGET FOR INITIAL BUDGET PERIOD				DIRECT COSTS ONLY		FROM	THROUGH
						1-Sep-18	31-Aug-19
PERSONNEL (Applicant organization only)				DOLLAR AMOUNT REQUESTED (omit cents)			
NAME	ROLE ON PROJECT	TYPE APPT. (months)	% EFFORT ON PROJ.	INST. BASE SALARY	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
Phillip Coffin, MD		12	0.40000	185,100	74,040	-	74,040
<b>SUBTOTALS</b>					<b>74,040</b>	<b>-</b>	<b>74,040</b>
<b>CONSULTANT COSTS</b>							
<b>EQUIPMENT (Itemize)</b>							
<b>SUPPLIES (Itemize by category)</b>							
<b>TRAVEL</b>							
					INPATIENT		
					OUTPATIENT		
<b>ALTERATIONS AND RENOVATIONS (Itemize by category)</b>							
<b>OTHER EXPENSES (Itemize by category)</b>							
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>74,040</b>
CONSORTIUM/CONTRACTUAL				TOTAL Subcontract			<b>45,768</b>
				FACILITIES AND ADMINISTRATIVE COSTS			<b>7,819</b>
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 9a, Face Page)</b>							<b>127,627</b>

Principal Investigator/Program Director (Last, first, middle):					FROM	THROUGH		
DETAILED BUDGET FOR INITIAL BUDGET PERIOD			DIRECT COSTS ONLY		1-Sep-19	31-Aug-20		
PERSONNEL (Applicant organization only)			TYPE APPT. (months)	% EFFORT ON PROJ.	INST. BASE SALARY	DOLLAR AMOUNT REQUESTED (omit cents)		
NAME	ROLE ON PROJECT	SALARY REQUESTED				FRINGE BENEFITS	TOTALS	
Phillip Coffin, MD		12	0.40000	185,100	74,040	-	74,040	
<b>SUBTOTALS</b>					<b>74,040</b>	<b>-</b>	<b>74,040</b>	
<b>CONSULTANT COSTS</b>								
<b>EQUIPMENT (Itemize)</b>								
<b>SUPPLIES (Itemize by category)</b>								
<b>TRAVEL</b>								
			INPATIENT					
			OUTPATIENT					
<b>ALTERATIONS AND RENOVATIONS (Itemize by category)</b>								
<b>OTHER EXPENSES (Itemize by category)</b>								
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>74,040</b>	
CONSORTIUM/CONTRACTUAL			TOTAL Subcontract				<b>45,768</b>	
			FACILITIES AND ADMINISTRATIVE COSTS				<b>7,819</b>	
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 9a, Face Page)</b>							<b>127,627</b>	
Page _____							Form Page 2	

Principal Investigator/Program Director (Last, first, middle):								
DETAILED BUDGET FOR INITIAL BUDGET PERIOD				DIRECT COSTS ONLY		FROM	THROUGH	
						1-Sep-20	31-Aug-21	
PERSONNEL (Applicant organization only)				TYPE APPT. (months)	% EFFORT ON PROJ.	INST. BASE SALARY	DOLLAR AMOUNT REQUESTED (omit cents)	
NAME	ROLE ON PROJECT						SALARY REQUESTED	FRINGE BENEFITS
Phillip Coffin, MD		12	0.40000	185,100	74,040	-	74,040	
SUBTOTALS						74,040	-	74,040
CONSULTANT COSTS								-
EQUIPMENT (Itemize)								-
SUPPLIES (Itemize by category)								-
TRAVEL								-
INPATIENT								-
OUTPATIENT								-
ALTERATIONS AND RENOVATIONS (Itemize by category)								-
OTHER EXPENSES (Itemize by category)								-
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>								<b>74,040</b>
CONSORTIUM/CONTRACTUAL				TOTAL Subcontract				<b>45,768</b>
				FACILITIES AND ADMINISTRATIVE COSTS				<b>7,819</b>
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 9a, Face Page)</b>								<b>127,627</b>

**City and County of San Francisco (CCSF)**

Budget Justification

Year One: September 1, 2016 – August 31, 2017  
Project Period: September 1, 2016 – August 31, 2021

**Principal Investigator – Coffin, Phillip, MD**

Dr. Coffin is Director of the Substance Use Research Unit at the San Francisco Dept. of Public Health (SFDPH). He is a board-certified infectious disease specialist with expertise in HIV treatment adherence, epidemiology of substance use trends, and evaluation of pharmacologic interventions for substance use. As the "candidate" for this K24 award, Dr. Coffin will complete career development activities, training in responsible conduct of research, and mentoring development work, as well as provide the mentoring as described in the application. Dr. Coffin will lead and provide oversight for the overall scientific, operational, and administrative aspects of the study. He will oversee the day-to-day management of the regulatory and clinical activities for this study. He will directly supervise the study coordinator and data analyst and work closely with the biostatistician. Dr. Coffin will ensure that all staff adheres to regulatory guidelines, and that any human subjects concerns are reported in a timely manner. He will be available on-call for study staff questions and will meet regularly with staff to discuss research progress and concerns. Dr. Coffin will initiate and serve as an author on study publications and present results at scientific meetings.

City and County of San Francisco (CCSF - San Francisco Department of Public Health (SFDPH))

**A. Personnel**

1. Principal Investigator – Coffin, Phillip MD (4.8 person months)

Annual Salary	\$185,100
4.8 Person Months	\$ 74,040
32% Mandatory Fringe Benefits	<u>\$ 23,692</u>
Year One:	\$ 97,732

Total Year One CCSF Personnel: \$97,732

*Funding Requested Each Following Year:*

Year Two: 4.8 Person Months @ \$74,040 + 32% Fringe @ \$23,692 = \$97,732  
Year Three: 4.8 Person Months @ \$74,040 + 32% Fringe @ \$23,692 = \$97,732  
Year Four: 4.8 Person Months @ \$74,040 + 32% Fringe @ \$23,692 = \$97,732  
Year Five: 4.8 Person Months @ \$74,040 + 32% Fringe @ \$23,692 = \$97,732

B. Consultant Costs N/A

C. Equipment N/A

D. Travel N/A

E. Participant/Trainee Support N/A

F. Other Direct Costs \$49,684

Contractual/Consortium

1. Public Health Foundation Enterprises (PHFE)

[See "PHFE Budget Justification" for detailed budget]

Total Year PHFE Sub contractual: \$49,684

*Funding Requested Each Following Year:*

Year Two: \$47,928  
Year Three: \$45,768  
Year Four: \$45,768  
Year Five: \$45,768

## 2. University of California, San Francisco (UCSF)

Co-Investigator – Vittinghoff, Eric (*effort in-kind*)

Dr. Eric Vittinghoff, Biostatistician, has extensive research, beginning with the landmark Heart and Estrogen/Progestin Study (HERS), the first to show that hormone therapy does not prevent CHD events, and other trials in women's health, including PRIDE and ULTRA. He has also collaborated with the San Francisco Department of Public Health on several previous studies, including published clinical trials of Aripiprazole, Mirtazapine and Bupropion, ongoing trials of naltrexone and mirtazapine for methamphetamine-using and alcohol-using men who have sex with men (MSM), trials of behavioral HIV prevention interventions for MSM, and several studies addressing opioid use, opioid overdose, and the use of naloxone, including the Naloxone for Opioid Safety Evaluation that forms the foundation for the proposed project. In close collaboration with Dr. Coffin, Dr. Vittinghoff will provide biostatistical support and consultation during the planning, conduct and analysis phase of the study. In particular, he will support the development of data collection instruments, ensuring high quality of the data collected, and developing data analysis plans to effectively address the research questions and specific aims of the study. Dr. Vittinghoff will collaborate closely with Dr. Coffin in the secondary data analysis, and publication of study results. Dr. Vittinghoff will devote his effort in-kind in years one through five. Dr. Vittinghoff is also involved in the career development element of this proposal, as addressed in his Letter of Support.

Total Year UCSF Sub contractual: \$0 (*effort in-kind*)

*Funding Requested Each Following Year:*

Year Two: \$0 (*effort in-kind*)  
Year Three: \$0 (*effort in-kind*)  
Year Four: \$0 (*effort in-kind*)  
Year Five: \$0 (*effort in-kind*)

Total Year One Contractual/Consortium: \$49,684

*Funding Requested Each Following Year:*

Year Two: \$47,928  
Year Three: \$45,768  
Year Four: \$45,768  
Year Five: \$45,768

G. Total Year One Direct Costs \$147,416 (\$97,732 Personnel + \$49,684 Contractual)

*Funding Requested Each Following Year:*

Year Two: \$145,660 (\$97,928 Personnel + \$47,928 Contractual)  
Year Three: \$143,500 (\$97,732 Personnel + \$45,768 Contractual)  
Year Four: \$143,500 (\$97,732 Personnel + \$45,768 Contractual)  
Year Five: \$147,462 (\$97,732 Personnel + \$45,768 Contractual)

H. Indirect Costs – Facilities & Administrative (F&A)

Indirect Costs (8% of DPH salaries & fringe) = \$122,732 salaries & fringe x 8% F&A = \$9,819

Total Year One Indirect Costs: \$9,819

*Funding Requested Each Following Year:*

*Year Two: \$97,732 salaries & fringe x 8% F&A = \$7,819*

*Year Three: \$97,732 salaries & fringe x 8% F&A = \$7,819*

*Year Four: \$97,732 salaries & fringe x 8% F&A = \$7,819*

*Year Five \$97,732 salaries & fringe x 8% F&A = \$7,819*

Total Year One CCSF Budget: \$157,235 (\$147,416 Direct Costs + \$9,819 Indirect Costs)

*Funding Requested Each Following Year:*

*Year Two: \$153,479 (\$145,660 Direct Costs + \$7,819 Indirect Costs)*

*Year Three: \$151,319 (\$143,500 Direct Costs + \$7,819 Indirect Costs)*

*Year Four: \$151,319 (\$143,500 Direct Costs + \$7,819 Indirect Costs)*

*Year Five: \$151,319 (\$143,500 Direct Costs + \$7,819 Indirect Costs)*



**Grant Number:** 1K24DA042720-01  
**FAIN:** K24DA042720

**Principal Investigator(s):**  
PHILLIP O COFFIN, MD

**Project Title:** Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV

Mr. Shaikh, Sajid  
Senior Administrative Analyst  
1380 Howard Street, Suite 423A  
San Francisco, CA 941030000

**Award e-mailed to:** barbara.garcia@sfdph.org

**Period Of Performance:**  
**Budget Period:** 09/01/2016 – 08/31/2017  
**Project Period:** 09/01/2016 – 08/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$157,235 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to SAN FRANCISCO DEPT OF PUBLIC HEALTH in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number K24DA042720. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,



EDITH L. DAVIS  
Grants Management Officer  
NATIONAL INSTITUTE ON DRUG ABUSE

Additional information follows

---

**SECTION I – AWARD DATA – 1K24DA042720-01****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$74,040
Fringe Benefits	\$23,692
Personnel Costs (Subtotal)	\$97,732
Other	\$49,684

Federal Direct Costs	\$147,416
Federal F&A Costs	\$9,819
Approved Budget	\$157,235
Total Amount of Federal Funds Obligated (Federal Share)	\$157,235
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$157,235</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$157,235**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$157,235	\$157,235
2	\$153,479	\$153,479
3	\$151,319	\$151,319
4	\$151,319	\$151,319
5	\$151,319	\$151,319

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

**CFDA Name:** Drug Abuse and Addiction Research Programs  
**CFDA Number:** 93.279  
**EIN:** 1946000417A8  
**Document Number:** KDA042720A  
**PMS Account Type:** P (Subaccount)  
**Fiscal Year:** 2016

IC	CAN	2016	2017	2018	2019	2020
DA	8472644	\$157,235	\$153,479	\$151,319	\$151,319	\$151,319

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** MC/JHK / **OC:** 415L / **Released:** PFLEMING 08/02/2016  
**Award Processed:** 08/09/2016 12:04:28 AM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 1K24DA042720-01**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 1K24DA042720-01**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget

- period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
  - f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part § 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) K24DA042720. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**  
Additional Costs

---

The award amount for the current year is based upon IRG/Council recommendations, cost analysis, program priorities and availability of funds.

**Midcareer Investigator Award in Patient-Oriented Research (Parent K24)**

<http://grants.nih.gov/grants/guide/pa-files/PA-14-047.html> This Career award requires between 3.00 and 6.00 person months' effort (25% and 50%) be devoted to the patient-oriented research program and mentoring that are part of this award.

Future year funding for this Mid-Career Investigator Award in Patient-Oriented Research is contingent upon acquiring additional Federal and/or private support for this project.

**Consortium** This award includes funds awarded for consortium activities. Consortia are to be established and administered as described in the NIH Grants Policy Statement (NIHGPS). The referenced section of the NIH Grants Policy Statement is available at Part II.15. Consortium Agreements - <http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>

**NIDA Award Terms** All grantees must acknowledge funding received from the National Institute on Drug Abuse at the National Institutes of Health when issuing statements, press releases, and requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with NIDA money. (NIH Grants Policy Statement, October/November 2015, <http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>.)

In conjunction with this requirement, in order to most effectively disseminate research results, advance notice should be given to NIDA that research finds are about to be published so that we may coordinate accurate and timely release to the media. This information will be embargoed until the publication date. Any press notification should be coordinated with the NIDA Press Officer who can be reached at (301) 443-6245.

NIDA has an interest in supporting HIV/AIDS and infectious disease research. The purpose of this support is to develop effective prevention, treatment, and service strategies for drug abusing youth and adults. To that end, awardees are encouraged to make every effort to incorporate scientific questions related to HIV/AIDS and other infectious diseases into research protocols. Principal Investigators will be required to provide information related to the development of research in this area in annual progress reports to allow NIDA to assess progress regarding HIV/AIDS research.

The National Institute on Drug Abuse (NIDA) encourages data harmonization to increase comparability, collaboration, and scientific yield of research on drug abuse. Towards that end, NIDA strongly encourages human-subject studies to incorporate a series of measures from the Substance Abuse and Addiction Core and Specialty collections, which are available in the PhenX Toolkit ([www.phenxtoolkit.org](http://www.phenxtoolkit.org)). For more information about NIDA's data harmonization efforts, please see NOT-DA-12-008 at <http://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html>.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Amy M Bucheimer  
**Email:** [bucheimera@mail.nih.gov](mailto:bucheimera@mail.nih.gov) **Phone:** 301-443-6710

**Program Official:** Jagjitsingh H. Khalsa  
**Email:** [jk98p@nih.gov](mailto:jk98p@nih.gov) **Phone:** (301) 443-2159

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 1K24DA042720-01

**INSTITUTION: SAN FRANCISCO DEPT OF PUBLIC HEALTH**

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$74,040	\$74,040	\$74,040	\$74,040	\$74,040
Fringe Benefits	\$23,692	\$23,692	\$23,692	\$23,692	\$23,692
Personnel Costs (Subtotal)	\$97,732	\$97,732	\$97,732	\$97,732	\$97,732
Other	\$49,684	\$47,928	\$45,768	\$45,768	\$45,768
TOTAL FEDERAL DC	\$147,416	\$145,660	\$143,500	\$143,500	\$143,500
TOTAL FEDERAL F&A	\$9,819	\$7,819	\$7,819	\$7,819	\$7,819
TOTAL COST	\$157,235	\$153,479	\$151,319	\$151,319	\$151,319

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	8%	8%	8%	8%	8%
F&A Cost Base 1	\$122,732	\$97,732	\$97,732	\$97,732	\$97,732
F&A Costs 1	\$9,819	\$7,819	\$7,819	\$7,819	\$7,819



Edwin M. Lee  
Mayor

Barbara A. Garcia, MPA  
Director of Health

**TO:** Angela Calvillo, Clerk of the Board of Supervisors  
**FROM:** Barbara A. Garcia, MPA  
Director of Health  
**DATE:** October 27, 2016  
**SUBJECT:** Grant Accept and Expend  
**GRANT TITLE:** Mid-Career Award in Patient-Oriented Substance Use  
Research Addressing Opioids, Chronic Pain, and HIV -  
\$157,235

---

Attached please find the original and 2 copies of each of the following:

- Proposed grant resolution, original signed by Department
- Grant information form, including disability checklist -
- Budget and Budget Justification
- Grant application: Not Applicable. No application submitted.
- Agreement / Award Letter
- Other (Explain):

**Special Timeline Requirements:**

**Departmental representative to receive a copy of the adopted resolution:**

Name: Richelle-Lynn Mojica

Phone: 255-3555

Interoffice Mail Address: Dept. of Public Health, Grants Administration for  
Community Programs, 1380 Howard St.


Certified copy required Yes

No

OFFICE OF THE MAYOR  
SAN FRANCISCO



EDWIN M. LEE

TO: Angela Calvillo, Clerk of the Board of Supervisors  
FROM: ~~for~~ Mayor Edwin M. Lee   
RE: Accept and Expend Grant - Mid-Career Award in Patient-Oriented  
Substance Use Research Addressing Opioids, Chronic Pain, and HIV -  
\$157,235  
DATE: November 15, 2016

---

Attached for introduction to the Board of Supervisors is a resolution retroactively authorizing the San Francisco Department of Public Health to accept and expend a grant in the amount of \$157,235 from National Institutes of Health to participate in a program entitled Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV for the period of September 1, 2016, through August 31, 2017.

Should you have any questions, please contact Nicole Elliott at (415) 554-7940.

RECEIVED  
BOARD OF SUPERVISORS  
SAN FRANCISCO  
2016 NOV 15 PM 2:13  
BY: 